#BEGIN_DRUGCARD DB00666

# AHFS_Codes:
68:18.00

# ATC_Codes:
H01CA02

# Absorption:
Rapidly absorbed into the systemic circulation after intranasal administration. Bioavailability from a 400 &micro;g dose averaged 2.8% (range 1.2 to 5.6%). Not absorbed after oral administration.

# Biotransformation:
Enzymatic hydrolysis.

# Brand_Mixtures:
Not Available

# Brand_Names:
Synarel

# CAS_Registry_Number:
76932-56-4

# ChEBI_ID:
Not Available

# Chemical_Formula:
C66H83N17O13

# Chemical_IUPAC_Name:
N-(5-carbamimidamido-1-{2-[(carbamoylmethyl)carbamoyl]pyrrolidin-1-yl}-1-oxopentan-2-yl)-2-{2-[2-(3-hydroxy-2-{2-[3-(1H-imidazol-4-yl)-2-[(5-oxopyrrolidin-2-yl)formamido]propanamido]-3-(1H-indol-3-yl)propanamido}propanamido)-3-(4-hydroxyphenyl)propanamido]-3-(naphthalen-2-yl)propanamido}-4-methylpentanamide

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
2188783

# Description:
A potent synthetic agonist of gonadotropin-releasing hormone with 3-(2-naphthyl)-D-alanine substitution at residue 6. Nafarelin has been used in the treatments of central precocious puberty and endometriosis. [PubChem]

# Dosage_Forms:
Aerosol, metered	Nasal

# Drug_Category:
Antiendometriotic agent
Fertility Agents, Female
Gonadotropin-releasing hormones

# Drug_Interactions:
Not Available

# Drug_Reference:
1531576	Burry KA: Nafarelin in the management of endometriosis: quality of life assessment. Am J Obstet Gynecol. 1992 Feb;166(2):735-9.
1531579	Henzl MR: Gonadotropin-releasing hormone analogs: update on new findings. Am J Obstet Gynecol. 1992 Feb;166(2):757-61.
1830521	Saltiel E, Garabedian-Ruffalo SM: Pharmacologic management of endometriosis. Clin Pharm. 1991 Jul;10(7):518-31.
2140979	Chrisp P, Goa KL: Nafarelin. A review of its pharmacodynamic and pharmacokinetic properties, and clinical potential in sex hormone-related conditions. Drugs. 1990 Apr;39(4):523-51.
2151003	Letassy NA, Thompson DF, Britton ML, Suda RR Sr: Nafarelin acetate: a gonadotropin-releasing hormone agonist for the treatment of endometriosis. DICP. 1990 Dec;24(12):1204-9.
7996307	Garner C: Uses of GnRH agonists. J Obstet Gynecol Neonatal Nurs. 1994 Sep;23(7):563-70.
9622415	Hugues JN, Cedrin Durnerin IC: Revisiting gonadotrophin-releasing hormone agonist protocols and management of poor ovarian responses to gonadotrophins. Hum Reprod Update. 1998 Jan-Feb;4(1):83-101.

# Drug_Type:
Approved
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
Not Available

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Nafarelin

# HET_ID:
Not Available

# Half_Life:
3 hours

# InChI_Identifier:
InChI=1S/C66H83N17O13/c1-36(2)25-48(58(89)76-47(13-7-23-71-66(68)69)65(96)83-24-8-14-54(83)64(95)73-33-55(67)86)77-60(91)50(28-38-15-18-39-9-3-4-10-40(39)26-38)78-59(90)49(27-37-16-19-43(85)20-17-37)79-63(94)53(34-84)82-61(92)51(29-41-31-72-45-12-6-5-11-44(41)45)80-62(93)52(30-42-32-70-35-74-42)81-57(88)46-21-22-56(87)75-46/h3-6,9-12,15-20,26,31-32,35-36,46-54,72,84-85H,7-8,13-14,21-25,27-30,33-34H2,1-2H3,(H2,67,86)(H,70,74)(H,73,95)(H,75,87)(H,76,89)(H,77,91)(H,78,90)(H,79,94)(H,80,93)(H,81,88)(H,82,92)(H4,68,69,71)

# InChI_Key:
InChIKey=RWHUEXWOYVBUCI-UHFFFAOYSA-N

# Indication:
For treatment of central precocious puberty (true precocious puberty, GnRH-dependent precocious precocity, complete isosexual precocity) in children of both sexes and for the treatment of endometriosis.

# KEGG_Compound_ID:
C07613

# KEGG_Drug_ID:
Not Available

# LIMS_Drug_ID:
666

# Mechanism_Of_Action:
Like GnRH, initial or intermittent administration of nafarelin stimulates release of the gonadotropins luteinizing hormone (LH) and follicle-stimulating hormone (FSH) from the pituitary gland, which in turn transiently increases production of estradiol in females and testosterone in both sexes. However, with continuous daily administration, nafarelin continuously occupies the GnRH receptor, leading to a reversible down-regulation of the GnRH receptors in the pituitary gland and desensitization of the pituitary gonadotropes. This causes a significant and sustained decline in the production of LH and FSH. A decline in gonadotropin production and release causes a dramatic reversible decrease in synthesis of estradiol, progesterone, and testosterone by the ovaries or testes. Like normal endometrium, endometriotic implants contain estrogen receptors. Estrogen stimulates the growth of endometrium. Use of nafarelin induces anovulation and amenorrhea and decreases serum concentrations of estradiol to the postmenopausal range, which induces atrophy of endometriotic implants. However, nafarelin does not abolish the underlying pathophysiology of endometriosis. In children with central precocious puberty receiving nafarelin, serum LH, testosterone, and estradiol concentrations return to prepubertal levels. This results in the supression of secondary sexual characteristics and decrased rate of linear growth and skeletal maturation. Following disconinuation of nafarelin, the effects of the drug is reversed, meaning FSH and LH concentrations usually return to pretreatment levels.

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
1322.4713

# Molecular_Weight_Mono:
1321.635625827

# Organisms_Affected:
Humans and other mammals

# PDB_Experimental_ID:
Not Available

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
PA164754805

# Pharmacology:
Nafarelin is a potent agonistic analog of gonadotropin-releasing hormone (GnRH). At the onset of administration, nafarelin stimulates the release of the pituitary gonadotropins, luteinizing hormone (LH) and follicle-stimulating hormone (FSH), resulting in a temporary increase of gonadal steroidogenesis. Repeated dosing abolishes the stimulatory effect on the pituitary gland. Twice daily administration leads to decreased secretion of gonadal steroids by about 4 weeks; consequently, tissues and functions that depend on gonadal steroids for their maintenance become quiescent. After nafarelin therapy is discontinued, pituitary and ovarian function normalize and estradiol serum concentrations increase to pretreatment levels. Recurrences of endometriosis are frequent after cessation of any hormonal therapy, or surgery that leaves the ovaries and/or uterus intact.

# Predicted_LogP_Hydrophobicity:
1.21

# Predicted_LogS:
-4.9

# Predicted_Water_Solubility:
1.66e-02 g/l

# Primary_Accession_No:
DB00666

# Protein_Binding:
Approximately 80%.

# PubChem_Compound_ID:
25077649

# PubChem_Substance_ID:
46506496

# RxList_Link:
http://www.rxlist.com/cgi/generic2/nafarelin.htm

# Salts:
Not Available

# Secondary_Accession_No:
APRD01129

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
CC(C)CC(NC(=O)C(CC1=CC2=CC=CC=C2C=C1)NC(=O)C(CC1=CC=C(O)C=C1)NC(=O)C(CO)NC(=O)C(CC1=CNC2=CC=CC=C12)NC(=O)C(CC1=CNC=N1)NC(=O)C1CCC(=O)N1)C(=O)NC(CCCNC(N)=N)C(=O)N1CCCC1C(=O)NCC(N)=O

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Nafarelin acetate

# Synthesis_Reference:
Not Available

# Toxicity:
In experimental animals, a single subcutaneous administration of up to 60 times the recommended human dose (on a &micro;g/kg basis, not adjusted for bioavailability) had no adverse effects. At present, there is no clinical evidence of adverse effects following overdosage of GnRH analogs.

# Update_Date:
2013-02-08 16:19:32 -0700

# Wikipedia_Link:
http://en.wikipedia.org/wiki/Nafarelin

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_1_Cellular_Location:
Membrane
multi-pass membrane protein

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
11752352	Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.
14644830	Valle RF, Sciarra JJ: Endometriosis: treatment strategies. Ann N Y Acad Sci. 2003 Nov;997:229-39.
14687742	Suh J, Lee E, Hwang S, Yoon S, Yoon BK, Bae D, Choi D: Dose of GnRH agonist (nafarelin acetate) affects intrafollicular PAPP-A expression in controlled ovarian hyperstimulation cycle. Eur J Obstet Gynecol Reprod Biol. 2004 Jan 15;112(1):65-8.
17097577	Batzer FR: GnRH analogs: options for endometriosis-associated pain treatment. J Minim Invasive Gynecol. 2006 Nov-Dec;13(6):539-45.
1830521	Saltiel E, Garabedian-Ruffalo SM: Pharmacologic management of endometriosis. Clin Pharm. 1991 Jul;10(7):518-31.
2137975	Barbieri RL: Comparison of the pharmacology of nafarelin and danazol. Am J Obstet Gynecol. 1990 Feb;162(2):581-5.
2140979	Chrisp P, Goa KL: Nafarelin. A review of its pharmacodynamic and pharmacokinetic properties, and clinical potential in sex hormone-related conditions. Drugs. 1990 Apr;39(4):523-51.
2151003	Letassy NA, Thompson DF, Britton ML, Suda RR Sr: Nafarelin acetate: a gonadotropin-releasing hormone agonist for the treatment of endometriosis. DICP. 1990 Dec;24(12):1204-9.
7996307	Garner C: Uses of GnRH agonists. J Obstet Gynecol Neonatal Nurs. 1994 Sep;23(7):563-70.
9622415	Hugues JN, Cedrin Durnerin IC: Revisiting gonadotrophin-releasing hormone agonist protocols and management of poor ovarian responses to gonadotrophins. Hum Reprod Update. 1998 Jan-Feb;4(1):83-101.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
GNRHR

# Drug_Target_1_GenBank_ID_Gene:
L03380

# Drug_Target_1_GenBank_ID_Protein:
183422

# Drug_Target_1_GeneCard_ID:
GNRHR

# Drug_Target_1_Gene_Name:
GNRHR

# Drug_Target_1_Gene_Sequence:
>987 bp
ATGGCAAACAGTGCCTCTCCTGAACAGAATCAAAATCACTGTTCAGCCATCAACAACAGC
ATCCCACTGATGCAGGGCAACCTCCCCACTCTGACCTTGTCTGGAAAGATCCGAGTGACG
GTTACTTTCTTCCTTTTTCTGCTCTCTGCGACCTTTAATGCTTCTTTCTTGTTGAAACTT
CAGAAGTGGACACAGAAGAAAGAGAAAGGGAAAAAGCTCTCAAGAATGAAGCTGCTCTTA
AAACATCTGACCTTAGCCAACCTGTTGGAGACTCTGATTGTCATGCCACTGGATGGGATG
TGGAACATTACAGTCCAATGGTATGCTGGAGAGTTACTCTGCAAAGTTCTCAGTTATCTA
AAGCTTTTCTCCATGTATGCCCCAGCCTTCATGATGGTGGTGATCAGCCTGGACCGCTCC
CTGGCTATCACGAGGCCCCTAGCTTTGAAAAGCAACAGCAAAGTCGGACAGTCCATGGTT
GGCCTGGCCTGGATCCTCAGTAGTGTCTTTGCAGGACCACAGTTATACATCTTCAGGATG
ATTCATCTAGCAGACAGCTCTGGACAGACAAAAGTTTTCTCTCAATGTGTAACACACTGC
AGTTTTTCACAATGGTGGCATCAAGCATTTTATAACTTTTTCACCTTCAGCTGCCTCTTC
ATCATCCCTCTTTTCATCATGCTGATCTGCAATGCAAAAATCATCTTCACCCTGACACGG
GTCCTTCATCAGGACCCCCACGAACTACAACTGAATCAGTCCAAGAACAATATACCAAGA
GCACGGCTGAAGACTCTAAAAATGACGGTTGCATTTGCCACTTCATTTACTGTCTGCTGG
ACTCCCTACTATGTCCTAGGAATTTGGTATTGGTTTGATCCTGAAATGTTAAACAGGTTG
TCAGACCCAGTAAATCACTTCTTCTTTCTCTTTGCCTTTTTAAACCCATGCTTTGATCCA
CTTATCTATGGATATTTTTCTCTGTGA

# Drug_Target_1_General_Function:
Involved in rhodopsin-like receptor activity

# Drug_Target_1_General_References:
10366411	Kottler ML, Bergametti F, Carre MC, Morice S, Decoret E, Lagarde JP, Starzec A, Counis R: Tissue-specific pattern of variant transcripts of the human gonadotropin-releasing hormone receptor gene. Eur J Endocrinol. 1999 Jun;140(6):561-9.
1333190	Kakar SS, Musgrove LC, Devor DC, Sellers JC, Neill JD: Cloning, sequencing, and expression of human gonadotropin releasing hormone (GnRH) receptor. Biochem Biophys Res Commun. 1992 Nov 30;189(1):289-95.
7534732	Kakar SS, Grizzle WE, Neill JD: The nucleotide sequences of human GnRH receptors in breast and ovarian tumors are identical with that found in pituitary. Mol Cell Endocrinol. 1994 Dec;106(1-2):145-9.
8386108	Chi L, Zhou W, Prikhozhan A, Flanagan C, Davidson JS, Golembo M, Illing N, Millar RP, Sealfon SC: Cloning and characterization of the human GnRH receptor. Mol Cell Endocrinol. 1993 Feb;91(1-2):R1-6.
9259321	Grosse R, Schoneberg T, Schultz G, Gudermann T: Inhibition of gonadotropin-releasing hormone receptor signaling by expression of a splice variant of the human receptor. Mol Endocrinol. 1997 Aug;11(9):1305-18.
9272108	Kakar SS: Molecular structure of the human gonadotropin-releasing hormone receptor gene. Eur J Endocrinol. 1997 Aug;137(2):183-92.

# Drug_Target_1_HGNC_ID:
HGNC:4421

# Drug_Target_1_HPRD_ID:
00732

# Drug_Target_1_ID:
226

# Drug_Target_1_Locus:
4q21.2

# Drug_Target_1_Molecular_Weight:
37731

# Drug_Target_1_Name:
Gonadotropin-releasing hormone receptor

# Drug_Target_1_Number_of_Residues:
328

# Drug_Target_1_PDB_ID:
Not Available

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00001	7tm_1

# Drug_Target_1_Protein_Sequence:
>Gonadotropin-releasing hormone receptor
MANSASPEQNQNHCSAINNSIPLMQGNLPTLTLSGKIRVTVTFFLFLLSATFNASFLLKL
QKWTQKKEKGKKLSRMKLLLKHLTLANLLETLIVMPLDGMWNITVQWYAGELLCKVLSYL
KLFSMYAPAFMMVVISLDRSLAITRPLALKSNSKVGQSMVGLAWILSSVFAGPQLYIFRM
IHLADSSGQTKVFSQCVTHCSFSQWWHQAFYNFFTFSCLFIIPLFIMLICNAKIIFTLTR
VLHQDPHELQLNQSKNNIPRARLKTLKMTVAFATSFTVCWTPYYVLGIWYWFDPEMLNRL
SDPVNHFFFLFAFLNPCFDPLIYGYFSL

# Drug_Target_1_Reaction:
Not Available

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
Receptor for gonadotropin releasing hormone (GnRH) that mediate the action of GnRH to stimulate the secretion of the gonadotropic hormones (LH and FSH). This receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Isoform 2 may act a an inhibitor of GnRH-R signaling

# Drug_Target_1_SwissProt_ID:
P30968

# Drug_Target_1_SwissProt_Name:
GNRHR_HUMAN

# Drug_Target_1_Synonyms:
GnRH receptor
GnRH-R

# Drug_Target_1_Theoretical_pI:
9.93

# Drug_Target_1_Transmembrane_Regions:
39-58
78-97
116-137
165-184
213-232
282-300
307-326

# Drug_Target_2_Cellular_Location:
Membrane
multi-pass membrane protein

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
14644830	Valle RF, Sciarra JJ: Endometriosis: treatment strategies. Ann N Y Acad Sci. 2003 Nov;997:229-39.
14687742	Suh J, Lee E, Hwang S, Yoon S, Yoon BK, Bae D, Choi D: Dose of GnRH agonist (nafarelin acetate) affects intrafollicular PAPP-A expression in controlled ovarian hyperstimulation cycle. Eur J Obstet Gynecol Reprod Biol. 2004 Jan 15;112(1):65-8.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17097577	Batzer FR: GnRH analogs: options for endometriosis-associated pain treatment. J Minim Invasive Gynecol. 2006 Nov-Dec;13(6):539-45.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
1830521	Saltiel E, Garabedian-Ruffalo SM: Pharmacologic management of endometriosis. Clin Pharm. 1991 Jul;10(7):518-31.
2137975	Barbieri RL: Comparison of the pharmacology of nafarelin and danazol. Am J Obstet Gynecol. 1990 Feb;162(2):581-5.
2140979	Chrisp P, Goa KL: Nafarelin. A review of its pharmacodynamic and pharmacokinetic properties, and clinical potential in sex hormone-related conditions. Drugs. 1990 Apr;39(4):523-51.
2151003	Letassy NA, Thompson DF, Britton ML, Suda RR Sr: Nafarelin acetate: a gonadotropin-releasing hormone agonist for the treatment of endometriosis. DICP. 1990 Dec;24(12):1204-9.
7996307	Garner C: Uses of GnRH agonists. J Obstet Gynecol Neonatal Nurs. 1994 Sep;23(7):563-70.
9622415	Hugues JN, Cedrin Durnerin IC: Revisiting gonadotrophin-releasing hormone agonist protocols and management of poor ovarian responses to gonadotrophins. Hum Reprod Update. 1998 Jan-Feb;4(1):83-101.
9622415	Hugues JN, Cedrin Durnerin IC: Revisiting gonadotrophin-releasing hormone agonist protocols and management of poor ovarian responses to gonadotrophins. Hum Reprod Update. 1998 Jan-Feb;4(1):83-101.

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
GNRHR2

# Drug_Target_2_GenBank_ID_Gene:
AF403014

# Drug_Target_2_GenBank_ID_Protein:
16589056

# Drug_Target_2_GeneCard_ID:
GNRHR2

# Drug_Target_2_Gene_Name:
GNRHR2

# Drug_Target_2_Gene_Sequence:
>1140 bp
CATGTCTGCAGGCAACGGCACCCCTTGGGGTCAGCAGCGGGGGAGGAGGTCTGGGCTGGA
TCAGGAGTGGAGGTGGAGGGCTCAGAGCTGCCCACCTTCTCGGCAGCAGCCAAGGTCCGA
GTGGGAGTGACCATTGTGCTGTTTGTTTCTTCGGCTGGAGGGAACCTGGCAGTCCTGTGG
TCAGTGACACGGCGGGAACCCAGCCAGCTCCGCCCCTCTCCGGTCAGGAGACTCTTCATC
CATTTAGCAGCCGCCGACTTACTAGTCACTTTTGTGGTTATGCCCCTAGATGCCACCTGG
AATATCACTGTTCAATGGCTGGCTGTGGACATCGCATGTCGGACACTGATGTTCCTGAAA
CTAATGGCCACGTATTCTGCAGCTTTCCTGCCTGTGGTCATTGGATTGGACCGCCAGGCA
GCAGTACTCAACCCGCTTGGATCCCGTTCAGGTGTAAGGAAACTTCTGGGGGCAGCCTGG
GGACTTAGTTTCCTGCTTGCCTTCCCCCAGCTGTTCCTGTTCCACACGGTCCACTGAGCT
GGCCCAGTCCCTTTCACTCAGTGTGTCACCAAAGGCAGCTTCAAGGCTCAATGGCAAGAG
ACCACCTATAACCTCTTCACCTTCTGCTGCCTCTTTCTGCTGCCACTGACTGCCATGGCC
ATCTGCTATAGCCGCATTGTCCTCAGTGTGTCCAGGCCCCAGACAAGGAAGGGGAGCCAT
GCCCCTGCTGGTGAATTTGCCCTCCCCCGCTCCTTTGACAATTGTCCCCGTGTTCGTCTC
CGGGCCCTGAGACTGGCCCTGCTTATCTTGCTGACCTTCATCCTCTGCTGGACACCTTAT
TACCTACTGGGTATGTGGTACTGGTTCTCCCCCACCATGCTAACTGAAGTCCCTCCCAGC
CTGAGCCACATCCTTTTCCTCTTGGGCCTCCTCAATGCTCCTTTGGATCCTCTCCTCTAT
GGGGCCTTCACCCTTGGCTGCCGAAGAGGGCACCAAGAACTTAGTATAGACTCTTCTAAA
GAAGGGTCTGGGAGAATGCTCCAAGAGGAGATTCATGCCTTTAGACAGCTGGAAGTACAA
AAAACTGTGACATCAAGAAGGGCAGGAGAAACAAAAGGCATTTCTATAACATCTATCTGA

# Drug_Target_2_General_Function:
Involved in rhodopsin-like receptor activity

# Drug_Target_2_General_References:
11707068	Faurholm B, Millar RP, Katz AA: The genes encoding the type II gonadotropin-releasing hormone receptor and the ribonucleoprotein RBM8A in humans overlap in two genomic loci. Genomics. 2001 Nov;78(1-2):15-8.
11861490	Neill JD: GnRH and GnRH receptor genes in the human genome. Endocrinology. 2002 Mar;143(3):737-43.

# Drug_Target_2_HGNC_ID:
HGNC:16341

# Drug_Target_2_HPRD_ID:
11780

# Drug_Target_2_ID:
524

# Drug_Target_2_Locus:
1q12

# Drug_Target_2_Molecular_Weight:
41576

# Drug_Target_2_Name:
Gonadotropin-releasing hormone II receptor

# Drug_Target_2_Number_of_Residues:
0

# Drug_Target_2_PDB_ID:
Not Available

# Drug_Target_2_Pathway:
Not Available

# Drug_Target_2_Pfam_Domain_Function:
PF00001	7tm_1

# Drug_Target_2_Protein_Sequence:
Not Available

# Drug_Target_2_Reaction:
Not Available

# Drug_Target_2_Signals:
None

# Drug_Target_2_Specific_Function:
Receptor for gonadotropin releasing hormone II (GnRH II). This receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system (Potential)

# Drug_Target_2_SwissProt_ID:
Q96P88

# Drug_Target_2_SwissProt_Name:
GNRR2_HUMAN

# Drug_Target_2_Synonyms:
GnRH-II-R
Type II GnRH receptor

# Drug_Target_2_Theoretical_pI:
9.68

# Drug_Target_2_Transmembrane_Regions:
41-60
77-96
115-136
161-178
205-224
279-297
304-323

#END_DRUGCARD DB00666
